NAV

Poloxalene

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Poloxalene
DrugBank Accession Number
DB11451
Background

Ethylene oxide/propylene oxide copolymer is used as a food additive. It belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).

Type
Small Molecule
Groups
Investigational, Vet approved
Structure
Similar Structures
Weight
Average: 102.1317
Monoisotopic: 102.068079564
Chemical Formula
C5H10O2
Synonyms
  • Peg/ppg-24/34 triblock copolymer
  • Poloxalene
External IDs
  • SK&F 18,667
  • SK&F-18667
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as epoxides. These are compounds containing a cyclic ether with three ring atoms(one oxygen and two carbon atoms).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Epoxides
Sub Class
Not Available
Direct Parent
Epoxides
Alternative Parents
Oxacyclic compounds / Dialkyl ethers / Hydrocarbon derivatives
Substituents
Aliphatic heteromonocyclic compound / Dialkyl ether / Ether / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Oxacycle / Oxirane
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
V8B3K56SW0
CAS number
691397-13-4
InChI Key
RVGRUAULSDPKGF-UHFFFAOYSA-N
InChI
InChI=1S/C3H6O.C2H4O/c1-3-2-4-3;1-2-3-1/h3H,2H2,1H3;1-2H2
IUPAC Name
2-methyloxirane; oxirane
SMILES
C1CO1.CC1CO1

References

General References
  1. Lippke H, Vetter RL, Jacobson NL: Poloxalene for bloat prevention in lambs. J Anim Sci. 1969 Jun;28(6):819-21. [Article]
  2. Foote LE, Girouard RE Jr, Johnston JE, Rainey J, Brown PB, Willis WH: Poloxalene for prevention of legume bloat. J Dairy Sci. 1968 Apr;51(4):584-90. [Article]
  3. Bartley EE, Stiles DA, Meyer RM, Scheidy SF, Clark JG, Boren FW: Poloxalene for treatment of cattle with alfalfa bloat. J Am Vet Med Assoc. 1967 Aug 1;151(3):339-43. [Article]
  4. Rodgers JB, Kyriakides EC, Bochenek WJ: Effect of surfactant poloxalene 2930 on food intake, lipid absorption, and serum cholesterol in rats. Exp Mol Pathol. 1984 Apr;40(2):214-22. [Article]
  5. Bartley EE, Barr GW, Mickelsen R: Bloat in cattle. XVII. Wheat pasture bloat and its prevention with poloxalene. J Anim Sci. 1975 Sep;41(3):752-9. [Article]
  6. Stiles DA, Bartley EE, Erhart AB, Meyer RM, Boren FW: Bloat in cattle. 13. Efficacy of molasses-salt blocks containing poloxalene in control of alfalfa bloat. J Dairy Sci. 1967 Sep;50(9):1437-43. [Article]
  7. Kapuscinska B, Bochenek WJ, Peng SK, Rodgers JB: Poloxalene 2930, a hydrophobic surfactant that prevents atherosclerosis, alters composition of rabbit lipoproteins. Atherosclerosis. 1985 Nov;57(2-3):149-58. [Article]
  8. Bezeau LM, Clark RD, Gray RJ: Poloxalene as an anti-bloat compound and its effect on milk yield and composition. Can J Comp Med Vet Sci. 1967 Dec;31(12):352-3. [Article]
  9. Bochenek WJ, Kapuscinska B, Slowinska R, Rodgers JB: Alterations of secretory pattern of intestinal lipoproteins by the benzoyl ester derivative of poloxalene surfactant (BEP). Atherosclerosis. 1987 Apr;64(2-3):167-72. [Article]
  10. Essig HW, Shawver CB: Methods of administration of poloxalene for control of bloat in beef cattle grazing ladino clover. J Anim Sci. 1968 Nov;27(6):1669-73. [Article]
  11. Guan Y, Huang J, Zuo L, Xu J, Si L, Qiu J, Li G: Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism. Arch Pharm Res. 2011 Oct;34(10):1719-28. doi: 10.1007/s12272-011-1016-0. Epub 2011 Nov 12. [Article]
  12. Xia XJ, Tao ZH, Ren Y, Wang RY, Liu YL: [Preparation and in vitro study of buagafuran solid dispersions]. Yao Xue Xue Bao. 2008 May;43(5):548-52. [Article]
  13. Grau U: Chemical stability of insulin in a delivery system environment. Diabetologia. 1985 Jul;28(7):458-63. [Article]
  14. Dumortier G, El Kateb N, Sahli M, Kedjar S, Boulliat A, Chaumeil JC: Development of a thermogelling ophthalmic formulation of cysteine. Drug Dev Ind Pharm. 2006 Jan;32(1):63-72. [Article]
  15. Zhang S, Li N, Zheng L, Li X, Gao Y, Yu L: Aggregation behavior of pluronic triblock copolymer in 1-butyl-3-methylimidazolium type ionic liquids. J Phys Chem B. 2008 Aug 21;112(33):10228-33. doi: 10.1021/jp8035132. Epub 2008 Jul 26. [Article]
  16. Cunha-Filho MS, Alvarez-Lorenzo C, Martinez-Pacheco R, Landin M: Temperature-sensitive gels for intratumoral delivery of beta-lapachone: effect of cyclodextrins and ethanol. ScientificWorldJournal. 2012;2012:126723. doi: 10.1100/2012/126723. Epub 2012 Apr 24. [Article]
  17. Zhang X, Liu C, Yuan Y, Zhang S, Shan X, Sheng Y, Xu F: Key parameters affecting the initial leaky effect of hemoglobin-loaded nanoparticles as blood substitutes. J Mater Sci Mater Med. 2008 Jun;19(6):2463-70. doi: 10.1007/s10856-007-3358-1. Epub 2008 Jan 25. [Article]
  18. Qi H, Li L, Huang C, Li W, Wu C: Optimization and physicochemical characterization of thermosensitive poloxamer gel containing puerarin for ophthalmic use. Chem Pharm Bull (Tokyo). 2006 Nov;54(11):1500-7. [Article]
  19. Nambam JS, Philip J: Thermogelling properties of triblock copolymers in the presence of hydrophilic Fe3O4 nanoparticles and surfactants. Langmuir. 2012 Aug 21;28(33):12044-53. doi: 10.1021/la302310y. Epub 2012 Aug 9. [Article]
  20. El-Houssieny BM, Hamouda HM: Formulation and evaluation of clotrimazole from pluronic F127 gels. Drug Discov Ther. 2010 Feb;4(1):33-43. [Article]
  21. Yamaoka T, Takahashi Y, Fujisato T, Lee CW, Tsuji T, Ohta T, Murakami A, Kimura Y: Novel adhesion prevention membrane based on a bioresorbable copoly(ester-ether) comprised of poly-L-lactide and Pluronic: in vitro and in vivo evaluations. J Biomed Mater Res. 2001 Mar 15;54(4):470-9. [Article]
  22. Zhao L, Du J, Duan Y, Zang Y, Zhang H, Yang C, Cao F, Zhai G: Curcumin loaded mixed micelles composed of Pluronic P123 and F68: preparation, optimization and in vitro characterization. Colloids Surf B Biointerfaces. 2012 Sep 1;97:101-8. doi: 10.1016/j.colsurfb.2012.04.017. Epub 2012 Apr 24. [Article]
Human Metabolome Database
HMDB0032263
KEGG Drug
D01941
ChemSpider
23141
RxNav
1314414
ChEBI
32026

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility201.0 mg/mLALOGPS
logP0.04ALOGPS
logP0.37Chemaxon
logS0.54ALOGPS
pKa (Strongest Basic)-4.2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area12.53 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity15.46 m3·mol-1Chemaxon
Polarizability6.34 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-121.5347
predicted
DeepCCS 1.0 (2019)
[M+H]+123.4467
predicted
DeepCCS 1.0 (2019)
[M+Na]+131.45995
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:52 / Updated at February 21, 2021 18:53